 |
4 Diseases |  |
0 Trials |
|
0 Trials |  |
70 News |  |
- || Lazanda (fentanyl) / Assertio, Kyowa Kirin
PK/PD data, Review, Journal: Clinical and pharmacokinetics overview of intranasal administration of fentanyl. (Pubmed Central) - Dec 25, 2023
However, there is limited available literature about the serious adverse effects of INF in adults and children. Intranasal Fentanyl Spray (INFS) results in significantly higher plasma concentrations and has a lower T than oral transmucosal formulation, and the bioavailability of fentanyl in intranasal formulations is very high (89
- | Journal: Opioids for pain. (Pubmed Central) - Dec 22, 2022
Intranasal Fentanyl Spray (INFS) results in significantly higher plasma concentrations and has a lower T than oral transmucosal formulation, and the bioavailability of fentanyl in intranasal formulations is very high (89 No abstract available
- | Journal: Comparison table: Some oral/transdermal opioid analgesics. (Pubmed Central) - Dec 22, 2022
No abstract available No abstract available
- | Lazanda (fentanyl) / Assertio, Kyowa Hakko Kirin, Rapinyl (fentanyl) / Kyowa Kirin, Orexo, Zydus Cadila
Journal: The prevalence of off-label prescribing of transmucosal immediate-release fentanyl in France. (Pubmed Central) - May 26, 2022
The prevalence of off-label prescribing of TIRF in France is extremely high. A field survey is now needed 1) to better understand why TIRF is used in conditions not indicated in its marketing authorization, and in what clinical situations, and 2) to determine whether the benefit/risk ratio of such use is favorable.
- Lazanda (fentanyl) / Assertio, Kyowa Kirin
New P4 trial: Trial to evaluate the efficacy of fentanyl pectin nasal spray (FPNS) versus Physician Choice (PC) - Usual Care (UC), in patients with head and neck cancer undergoing radiotherapy. Studio per valutare l'efficacia del Fentanyl Pectin Spray Nasale (FPNS) rispetto ai trattamenti utilizzati nella normale pratica clinica, nei pazienti con tumore testa-collo sottoposti a radioterapia. (EUDRACT) - Nov 10, 2020
P4, N=158, Terminated, Sponsor: FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
- || Duragesic (fentanyl) / J&J
Clinical, Journal: Breakthrough pain in patients with head & neck cancer. A secondary analysis of IOPS MS study. (Pubmed Central) - Jul 7, 2020
BTcP in patients with H&N cancer is characterized by a larger number of episodes/day and the predictability, particularly with ingestion of food. The use of drugs for background analgesia and BTcP were conditioned by the possible interference with swallowing or local mucosal damage.
- || fentanyl citrate / Generic mfg., Lazanda (fentanyl) / Assertio, Kyowa Hakko Kirin
Clinical, Journal: Patient Satisfaction with Fentanyl Pectin Nasal Spray in Breakthrough Cancer Pain Management During Radiotherapy for Head and Neck Cancer. (Pubmed Central) - Jun 19, 2020
Patient quality of life was maintained throughout the radiotherapy period. This study showed, in a real-life setting, that a clear majority of H&N cancer patients treated with FPNS for BTcP throughout radiotherapy expressed satisfaction with this analgesic treatment.
- ||| fentanyl citrate / Generic mfg., Lazanda (fentanyl) / Assertio, Kyowa Hakko Kirin
1. Emergency ESWL if access (and nil contraindications) + IV / nasal fentanyl on table (as per @NICEComms) OR 2. Primary URS + stent Depends on #access to #surgery! #urology (Twitter) - Jan 9, 2020
- | fentanyl citrate / Generic mfg.
Journal: Effectiveness of fentanyl pectin nasal citrate in controlling episodes of breakthrough cancer pain triggered by routine radiotherapy procedures. (Pubmed Central) - Dec 28, 2019
In our knowledge, our study is the one of highest recruitment, and with the fastest response of BTCP treated with FPNS reported in advanced cancer patients undergoing radiotherapy. FPNS has proven to be highly effective in reducing the intensity of procedural BTCP in a very short period of time.
- || Lazanda (fentanyl) / Depomed, Kyowa Hakko Kirin
Clinical, Journal: Fentanyl nasal spray in a patient with end-stage COPD and severe chronic breathlessness. (Pubmed Central) - Dec 1, 2019
Prescription of fentanyl nasal spray for breathlessness should only be done as part of palliative treatment and requires close follow-up. http://bit.ly/2YdOjJ1.
- | fentanyl citrate / generics
Journal: Transmucosal fentanyl administration: sublingual, buccal, nasal - all the same? Treatment of breakthrough cancer pain (Pubmed Central) - Aug 15, 2019
The individual preparations differ considerably with regard to their pharmacological (e.g. bioavailability, cand t) and patient-relevant parameters (e.g. onset of action, potency and duration of effect). Fentanyl nasal spray is superior to the other forms of administration in terms of rapid onset of action and clinically relevant pain reduction and can thus be recommended as a treatment option for rapidly evolving and/or spontaneously occurring breakthrough cancer pain.
- | Lazanda (fentanyl) / Depomed, Kyowa Hakko Kirin
Journal: Factors influencing the use of opioids for breakthrough cancer pain: a secondary analysis of the IOPS-MS study. (Pubmed Central) - Jun 15, 2019
The use of opioids for breakthough cancer pain was effective and safe in a large sample of advanced cancer patients recruited in different stages of disease and settings. Doses of opioids proportional to opioid doses used for background analgesia, seem to guarantee both effectiveness and safety.
- | Lazanda (fentanyl) / Assertio, Kyowa Kirin
Trial completion, Enrollment change: ANTALGIP: Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy (clinicaltrials.gov) - May 13, 2019
P4, N=20, Completed, Sponsor: Central Hospital, Nancy, France
Doses of opioids proportional to opioid doses used for background analgesia, seem to guarantee both effectiveness and safety. Recruiting --> Completed | N=60 --> 20
- | Enrollment change: Cycling of Sedative Infusions in Critically Ill Pediatric Patients (clinicaltrials.gov) - Nov 23, 2018
P=N/A, N=25, Terminated, Sponsor: Javier Gelvez, MD
Recruiting --> Completed | N=60 --> 20 N=120 --> 25
- | Lazanda (fentanyl) / Assertio, Kyowa Kirin
Enrollment change, Trial termination: Lazanda in Cancer Patients Receiving Palliative Radiation (clinicaltrials.gov) - Mar 20, 2018
P2, N=6, Terminated, Sponsor: University of California, San Diego
N=120 --> 25 N=15 --> 6 | Recruiting --> Terminated; PI is leaving UCSD
- Lazanda (fentanyl) / Assertio, Kyowa Kirin
Trial initiation date: Fentanyl for Breakthrough Pain in the Emergency Department (clinicaltrials.gov) - Jan 11, 2018
P4, N=3, Terminated, Sponsor: M.D. Anderson Cancer Center
N=15 --> 6 | Recruiting --> Terminated; PI is leaving UCSD Initiation date: Feb 2013 --> Jan 2014
- | Lazanda (fentanyl) / Assertio, Kyowa Hakko Kirin
Clinical, Journal: Impact of Prophylactic Fentanyl Pectin Nasal Spray on Exercise-Induced Episodic Dyspnea in Cancer Patients: A Double-Blind, Randomized Controlled Trial. (Pubmed Central) - Dec 23, 2017
P2
FPNS was safe, reduced dyspnea at rest, and increased walk distance in before-after comparison. The placebo effect was substantial, which needs to be factored in future study designs.
- | Lazanda (fentanyl) / Assertio, Kyowa Kirin, Instanyl (fentanyl) / Takeda
Trial primary completion date: Safety of Intranasal Fentanyl (PecFent (clinicaltrials.gov) - Oct 26, 2017
P2/3, N=60, Recruiting, Sponsor: University Hospital, Grenoble
The placebo effect was substantial, which needs to be factored in future study designs. Trial primary completion date: Sep 2017 --> Dec 2017
- | Lazanda (fentanyl) / Assertio, Kyowa Kirin
Trial primary completion date: PARABONE: Pain Management With Pecfent in the Prevention of Pain Induced by Position in Radiotherapy (clinicaltrials.gov) - Jul 21, 2017
P3, N=120, Recruiting, Sponsor: Centre Henri Becquerel
Trial primary completion date: Sep 2017 --> Dec 2017 Trial primary completion date: Jul 2018 --> Dec 2018
- | Lazanda (fentanyl) / Assertio, Kyowa Kirin
Trial completion: Intranasal Fentanyl for Management of Pain Associated With Cystoscopic Procedures (clinicaltrials.gov) - May 11, 2017
P1, N=20, Completed, Sponsor: Richard C Reznichek, MD
Trial primary completion date: Jul 2018 --> Dec 2018 Recruiting --> Completed
- | Lazanda (fentanyl) / Assertio, Kyowa Kirin, Instanyl (fentanyl) / Takeda
Trial primary completion date: Safety of Intranasal Fentanyl (PecFent (clinicaltrials.gov) - May 3, 2017
P2/3, N=60, Recruiting, Sponsor: University Hospital, Grenoble
Recruiting --> Completed Trial primary completion date: Mar 2017 --> Sep 2017
- | Lazanda (fentanyl) / Assertio, Kyowa Kirin
Enrollment open: Lazanda in Cancer Patients Receiving Palliative Radiation (clinicaltrials.gov) - May 3, 2017
P2, N=15, Recruiting, Sponsor: University of California, San Diego
Trial primary completion date: Mar 2017 --> Sep 2017 Not yet recruiting --> Recruiting
- | Lazanda (fentanyl) / Assertio, Kyowa Kirin, Epistatus (midazolam oromucosal solution) / Veriton Pharma
Trial initiation date, Trial primary completion date: Nasal Fentanyl and Buccal Midazolam for Dying Patients (clinicaltrials.gov) - Apr 18, 2017
P4, N=20, Recruiting, Sponsor: Gloucestershire Hospitals NHS Foundation Trust
Not yet recruiting --> Recruiting Initiation date: Apr 2014 --> Jan 2017 | Trial primary completion date: Apr 2015 --> Jan 2018
- | Lazanda (fentanyl) / Assertio, Kyowa Kirin
New P2 trial: Lazanda in Cancer Patients Receiving Palliative Radiation (clinicaltrials.gov) - Mar 7, 2017
P2, N=15, Not yet recruiting, Sponsor: University of California, San Diego
- Lazanda (fentanyl) / Assertio, Kyowa Kirin
Enrollment change, Trial initiation date, Trial termination, Trial primary completion date: Fentanyl for Breakthrough Pain in the Emergency Department (clinicaltrials.gov) - Jan 23, 2017
P4, N=3, Terminated, Sponsor: M.D. Anderson Cancer Center
Initiation date: Apr 2014 --> Jan 2017 | Trial primary completion date: Apr 2015 --> Jan 2018 N=60 --> 3 | Initiation date: Jan 2014 --> Feb 2013 | Suspended --> Terminated | Trial primary completion date: Jan 2017 --> Oct 2014
- | Lazanda (fentanyl) / Assertio, Kyowa Kirin
New P4 trial: ANTALGIP: Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy (clinicaltrials.gov) - Aug 15, 2016
P4, N=60, Recruiting, Sponsor: Central Hospital, Nancy, France
- Lazanda (fentanyl) / Assertio, Kyowa Kirin
Trial primary completion date: PARABONE: Pain Management With Pecfent in the Prevention of Pain Induced by Position in Radiotherapy (clinicaltrials.gov) - Jul 28, 2016
P3, N=120, Recruiting, Sponsor: Centre Henri Becquerel
N=60 --> 3 | Initiation date: Jan 2014 --> Feb 2013 | Suspended --> Terminated | Trial primary completion date: Jan 2017 --> Oct 2014 Trial primary completion date: Jul 2016 --> Jul 2018
- Lazanda (fentanyl) / Assertio, Kyowa Kirin
Trial primary completion date: Intranasal Fentanyl for Management of Pain Associated With Cystoscopic Procedures (clinicaltrials.gov) - Apr 4, 2016
P1, N=20, Recruiting, Sponsor: Richard C Reznichek, MD
Trial primary completion date: Jul 2016 --> Jul 2018 Trial primary completion date: Jul 2015 --> Jul 2016
- | Lazanda (fentanyl) / Assertio, Kyowa Kirin
Trial completion: Lazanda Fentanyl Nasal Spray Pre Radiofrequency Nerve Ablations(RFA) of Lumbar Facet Joints (clinicaltrials.gov) - Mar 18, 2016
P4, N=23, Completed, Sponsor: Defense and Veterans Center for Integrative Pain Management
Trial primary completion date: Jul 2015 --> Jul 2016 Recruiting --> Completed
- Lazanda (fentanyl) / Assertio, Kyowa Kirin
Enrollment change, Trial withdrawal: FCNS: An Assessment of the Ability of Fentanyl Citrate Nasal Spray to Manage Breakthrough Pain in Cancer Patients. (clinicaltrials.gov) - Mar 1, 2016
P4, N=0, Withdrawn, Sponsor: James Graham Brown Cancer Center
Recruiting --> Completed N=40 --> 0 | Recruiting --> Withdrawn
- | Lazanda (fentanyl) / Assertio, Kyowa Kirin
New P4 trial: Lazanda Fentanyl Nasal Spray Pre Radiofrequency Nerve Ablations(RFA) of Lumbar Facet Joints (clinicaltrials.gov) - Oct 22, 2015
P4, N=20, Recruiting, Sponsor: Defense and Veterans Center for Integrative Pain Management
- | Lazanda (fentanyl) / Assertio, Kyowa Kirin
New P4 trial: Open Label Crossover Study Pharmacokinetics (PK) Study in Healthy Volunteers Receiving Various Forms of Fentanyl (clinicaltrials.gov) - Jun 12, 2015
P4, N=13, Completed, Sponsor: Depomed
- | Lazanda (fentanyl) / Assertio, Kyowa Kirin
Enrollment open: PARABONE: Pain Management With Pecfent in the Prevention of Pain Induced by Position in Radiotherapy (clinicaltrials.gov) - Jun 9, 2015
P3, N=120, Recruiting, Sponsor: Centre Henri Becquerel
N=40 --> 0 | Recruiting --> Withdrawn Not yet recruiting --> Recruiting
- | Lazanda (fentanyl) / Assertio, Kyowa Kirin, Instanyl (fentanyl) / Takeda
Enrollment open: Safety of Intranasal Fentanyl (PecFent (clinicaltrials.gov) - May 27, 2015
P2/3, N=60, Recruiting, Sponsor: University Hospital, Grenoble
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Lazanda (fentanyl) / Assertio, Kyowa Kirin
New P3 trial: PARABONE: Pain Management With Pecfent in the Prevention of Pain Induced by Position in Radiotherapy (clinicaltrials.gov) - Apr 27, 2015
P3, N=120, Not yet recruiting, Sponsor: Centre Henri Becquerel
- Lazanda (fentanyl) / Assertio, Kyowa Kirin
Trial suspension, Trial primary completion date: Fentanyl for Breakthrough Pain in the Emergency Department (clinicaltrials.gov) - Feb 10, 2015
P4, N=60, Suspended, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Terminated --> Suspended | Trial primary completion date: Jan 2016 --> Jan 2017
- || Lazanda (fentanyl) / Assertio, Kyowa Kirin, Instanyl (fentanyl) / Takeda
New P2/3 trial: Safety of Intranasal Fentanyl (PecFent (clinicaltrials.gov) - Nov 24, 2014
P2/3, N=60, Not yet recruiting, Sponsor: University Hospital, Grenoble
- Lazanda (fentanyl) / Assertio, Kyowa Kirin
Trial primary completion date: Intranasal Fentanyl for Management of Pain Associated With Cystoscopic Procedures (clinicaltrials.gov) - Nov 12, 2014
P1, N=20, Recruiting, Sponsor: Richard C Reznichek, MD
Terminated --> Suspended | Trial primary completion date: Jan 2016 --> Jan 2017 Trial primary completion date: Feb 2014 --> Jul 2015
- Lazanda (fentanyl) / Assertio, Kyowa Kirin
Enrollment change, Trial termination: Fentanyl for Breakthrough Pain in the Emergency Department (clinicaltrials.gov) - Oct 27, 2014
P4, N=3, Terminated, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Feb 2014 --> Jul 2015 N=60 --> 3 | Recruiting --> Terminated
- Lazanda (fentanyl) / Assertio, Kyowa Kirin
Enrollment open, Trial primary completion date: FCNS: An Assessment of the Ability of Fentanyl Citrate Nasal Spray to Manage Breakthrough Pain in Cancer Patients. (clinicaltrials.gov) - Oct 17, 2014
P4, N=40, Recruiting, Sponsor: James Graham Brown Cancer Center
N=60 --> 3 | Recruiting --> Terminated Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2016 --> Apr 2017
- Lazanda (fentanyl) / Assertio, Kyowa Kirin
Enrollment open: Fentanyl for Breakthrough Pain in the Emergency Department (clinicaltrials.gov) - Jan 9, 2014
P4, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2016 --> Apr 2017 Not yet recruiting --> Recruiting
- Lazanda (fentanyl) / Assertio, Kyowa Kirin, Epistatus (midazolam oromucosal solution) / Veriton Pharma
New P4 trial: Nasal Fentanyl and Buccal Midazolam for Dying Patients (clinicaltrials.gov) - Dec 9, 2013
P4, N=20, Not yet recruiting, Sponsor: Gloucestershire Hospitals NHS Foundation Trust
- Lazanda (fentanyl) / Assertio, Kyowa Kirin
Enrollment open: Intranasal Fentanyl for Management of Pain Associated With Cystoscopic Procedures (clinicaltrials.gov) - Oct 29, 2013
P1, N=20, Recruiting, Sponsor: Richard C Reznichek, MD
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Lazanda (fentanyl) / Assertio, Kyowa Kirin
New P4 trial: FCNS: An Assessment of the Ability of Fentanyl Citrate Nasal Spray to Manage Breakthrough Pain in Cancer Patients. (clinicaltrials.gov) - Apr 23, 2013
P4, N=40, Not yet recruiting, Sponsor: James Graham Brown Cancer Center
- | Lazanda (fentanyl) / Assertio, Kyowa Kirin
New P4 trial: Fentanyl for Breakthrough Pain in the Emergency Department (clinicaltrials.gov) - Mar 14, 2013
P4, N=60, Recruiting, Sponsor: M.D. Anderson Cancer Center
- ||||||| Lazanda (fentanyl) / Assertio, Kyowa Kirin
Trial completion: Long Term Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain (clinicaltrials.gov) - Jan 24, 2013
P3, N=403, Completed, Sponsor: Archimedes Development Ltd
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Lazanda (fentanyl) / Assertio, Kyowa Kirin
New P1 trial: Intranasal Fentanyl for Management of Pain Associated With Cystoscopic Procedures (clinicaltrials.gov) - Dec 25, 2012
P1, N=20, Recruiting, Sponsor: Richard C Reznichek, MD
- Trial termination: Cycling of Sedative Infusions in Critically Ill Pediatric Patients (clinicaltrials.gov) - Dec 5, 2012
P=N/A, N=120, Terminated, Sponsor: Javier Gelvez, MD
Active, not recruiting --> Completed Suspended --> Terminated; Unable to adequately enroll over a reasonable enrollment period.
- ||| Lazanda (fentanyl) / Assertio, Kyowa Kirin
HEOR: Qualipec: Patient Satisfaction and Quality of Life Impact - PecFent (clinicaltrials.gov) - Oct 1, 2012
P=N/A, N=150, Recruiting, Sponsor: Archimedes Development Ltd
- ||| Lazanda (fentanyl) / Assertio, Kyowa Kirin
HEOR: Qualipec: Patient Satisfaction and Quality of Life Impact - PecFent (clinicaltrials.gov) - Sep 24, 2012
P=N/A, N=300, Recruiting, Sponsor: Archimedes Development Ltd